Go to Homepage

Global

|

Clinical breakthroughs that transform lives 

A proud history of delivering high-quality treatments that continues today

At Merz Therapeutics, we are developing innovative medicines to improve patient outcomes. We’re focused on specialty neurology, where we are best-placed to make the most difference.

18

recent approvals*

5

Projects in partnership

18%

of 23/24 Sales reinvested into R&D 

> 150

professionals in R&D roles

* Between July 2021 to June 2024

Our pipeline at a glance

This table overviews our late-stage clinical development programs for Incobotulinumtoxin type A (XEOMIN®) and is updated in regular intervals. 
Last update: June 1st, 2025

FILTER BY STATUS

Phase 1

Phase 2

Phase 3

Approval

Indication

Lower Limb Spasticity

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Phase 3

Indication

Lower Limb Pediatric Spasticity

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Phase 3

Indication

Migraine

Therapeutic Area

Pain Management

Product

NT 201

Phase 3

Indication

Peripheral Neuropathic Pain

Therapeutic Area

Pain Management

Product

NT 201

Phase 2

Indication

Essential Tremor

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Phase 2

Latest label modifications and approvals**

Indication

Pediatric Upper
Limb Spasticity
(Excluding Cerebral Palsy)

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approved in the US

Approval

Indication

Spasticity (Label extension)

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approval

Indication

Pediatric Sialorrhea

Therapeutic Area

Neurology

Product

NT 201

Approved in Europe, North America

Approval

Indication

Lower Limb Spasticity

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approved in the UK

Approval

Indication

Upper Limb Spasticity
(Label Extension)

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approved in Canada

Approval

Indication

Lower Limb Post 
Stroke Spasticity

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approved in Japan

(In partnership)

Approval

Indication

Upper Limb Post 
Stroke Spasticity

Therapeutic Area

Neurology / Movement Disorders

Product

NT 201

Approved in Japan

(In partnership)

Approval

**The table includes information on the markets of Merz Therapeutics subsidiaries and strategic partners. Approved brand name indications differ by region and country. Please refer to the current product information for the approval status in your country.

You might also like

Contact Icon

Press & Media

+49 (0)69 1503 2129 luke.mirceawillats@merz.ch

Human Resources

merztherapeutics@merz.com

Customer Service

More details

Corporate Development

More details

For other inquiries, please contact us here:

Contact

Platform change – You are leaving this page.

You are leaving this website. With respect to the content of the following page, as well as to links to other websites located on this page, Merz Therapeutics GmbH has no way of controlling the content of these sites. Merz Therapeutics GmbH assumes no responsibility for the content of these sites or the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.

Continue to url

Change of country – You are leaving this page.

You are leaving this website. The content of the following sites maintained by the parent company or another affiliated company, or links to other sites located on this site, is subject to the legal requirements of the country in which the site is maintained. Merz Therapeutics GmbH accepts no responsibility whatsoever for the content of these websites or for the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.

Continue to url